Nothing about our sourcing is hidden.
Every peptide used in a Vitruvia Clinic protocol arrives with a Certificate of Analysis: batch number, tested purity, laboratory, and release date. Both research-grade and human-grade options are available, chosen for each patient based on measured need and clinical context, never on inventory.
Published, not promised
Certificates of Analysis for every batch are made available to prescribed patients on request: the same document the clinic sees before releasing a batch.
Grade matched to context
Research-grade compounds are used only where clinically appropriate and disclosed. Human-grade pharmaceutical peptides are the default for anything prescribed for therapeutic use.
EU-registered supply chain
Compounding and sourcing sit inside EU-registered pharmacies and analytical laboratories with documented chain-of-custody from synthesis to dispensing.
Batch-level QA, published in the open.
The structure below reflects our live QA ledger. Entries shown here are illustrative examples of the data captured per batch; the current ledger is issued to prescribed patients alongside their dispense.
| Compound | Batch | Grade | Purity | Test date | Laboratory | Status |
|---|---|---|---|---|---|---|
| BPC-157 | BPC-2026-0417-A | Human-grade | 99.4% | 2026-04-22 | Eurofins BioPharma, DE | Released |
| Ipamorelin | IPA-2026-0331-B | Human-grade | 99.1% | 2026-04-04 | SGS Life Sciences, CH | Released |
| TB-500 (Thymosin β4) | TB4-2026-0210-C | Research-grade | 98.7% | 2026-02-16 | Eurofins BioPharma, DE | Released |
| CJC-1295 (no DAC) | CJC-2026-0129-A | Human-grade | 99.2% | 2026-02-01 | Intertek Pharmaceutical, UK | Released |
| GHK-Cu | GHK-2025-1215-B | Research-grade | 99.6% | 2025-12-19 | SGS Life Sciences, CH | Released |
Illustrative data structure. Live ledger issued to prescribed patients.